KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Account Payables (2020 - 2024)

Historic Change in Account Payables for AbCellera Biologics (ABCL) over the last 5 years, with Q3 2024 value amounting to $4.1 million.

  • AbCellera Biologics' Change in Account Payables changed N/A to $4.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $4.0 million, marking a year-over-year increase of 12727.95%. This contributed to the annual value of -$3.2 million for FY2022, which is 3185.25% up from last year.
  • Per AbCellera Biologics' latest filing, its Change in Account Payables stood at $4.1 million for Q3 2024.
  • In the past 5 years, AbCellera Biologics' Change in Account Payables registered a high of $24.3 million during Q4 2020, and its lowest value of -$32.7 million during Q3 2022.
  • For the 5-year period, AbCellera Biologics' Change in Account Payables averaged around $444437.5, with its median value being $1.6 million (2020).
  • As far as peak fluctuations go, AbCellera Biologics' Change in Account Payables plummeted by 447307.69% in 2021, and later skyrocketed by 42039.53% in 2022.
  • Quarter analysis of 5 years shows AbCellera Biologics' Change in Account Payables stood at $24.3 million in 2020, then dropped by 9.66% to $21.9 million in 2021, then plummeted by 93.04% to $1.5 million in 2022, then plummeted by 1166.47% to -$16.3 million in 2023, then surged by 125.52% to $4.1 million in 2024.
  • Its last three reported values are $4.1 million in Q3 2024, $4.7 million for Q2 2024, and -$4.9 million during Q1 2024.